Evidence map›Paper›PMID 39754648›Full record

ArticleTechniques in coloproctology2025

Long-term efficacy and safety of sacral neuromodulation for diarrhoea-predominant and mixed irritable bowel syndrome.

J Fassov, K L Høyer, L Lundby, S Laurberg, S M Scott, K Krogh

Registry-linked trialAbstract readEvaluation Study
PubMed Publisher
In one paragraph

Article in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01948973 (A Randomised, Controlled Crossover Study of Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01948973 nacompletednot on this map

A Randomised, Controlled Crossover Study of Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome

TypeinterventionalSponsorUniversity of AarhusRan2013 to 2018Enrolled21ConditionsIrritable Bowel SyndromeArmsSubsensory, OFF, Suprasensory
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J FassovDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark. janfas@rm.dk.ORCID 0000-0002-0600-223X
K L HøyerDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark.ORCID 0000-0002-3195-6561
L LundbyDepartment of Surgery, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark.ORCID 0000-0001-6612-3319
S LaurbergDepartment of Surgery, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark.ORCID 0000-0002-2284-0276
S M ScottNational Bowel Research Centre and GI Physiology Unit, Centre of Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK.
K KroghDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark.ORCID 0000-0001-9168-2403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIrritable bowel syndrome (IBS) is a very common condition worldwide. Treatment options for severe IBS are few. Sacral neuromodulation (SNM) for patients with IBS has been shown to reduce symptoms and improve quality of life in the medium term. This study aimed to evaluate the long-term effectiveness and safety of SNM in diarrhoea-predominant and mixed IBS.

methodsA prospective cohort of patients with IBS treated with SNM were evaluated 1, 3, 5, and 10 years after implantation. The primary end-point was a change in the Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome version questionnaire (GSRS-IBS) from baseline to 10-year follow-up (FU). Secondary end-points were change in the GSRS-IBS score from baseline to 5-year FU and change in the Irritable Bowel Syndrome-Impact Scale questionnaire (IBS-IS) from baseline to 5- and 10-year FU. Adverse events following SNM were observed.

resultsOf 36 patients treated with SNM, 23 were eligible for 5-year FU and 13 for 10-year FU. The GSRS-IBS score was significantly reduced at both 5-year (p < 0.0001) and 10-year (p = 0.0007) FU. The IBS-IS score was also significantly improved at both 5 years (p < 0.0001) and 10 years (p = 0.0002). Fifty-six adverse events were registered. Five patients were explanted because of adverse events.

conclusionSNM seems to offer an effective and safe treatment option for highly selected patients with diarrhoea-predominant and mixed IBS. CLINICAL

trial registrationThe present study has not been registered. The latest founding study was registered at ClinicalTrials.gov, NCT01948973.

Indexed as

DiarrheaElectric Stimulation TherapyIrritable Bowel SyndromeLumbosacral PlexusQuality of LifeAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesSeverity of Illness IndexSurveys and QuestionnairesTime FactorsCost-effectivenessEfficacyIrritable bowel syndromeSacral neuromodulationSafetyTreatment

Identifiers

PMID39754648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.